Less than two years after it was launched, San Francisco-based startup Cartography Biosciences has announced a deal with nearby biotech major, Gilead Sciences (Nasdaq: GILD).
Cartography was launched in July 2022 with $57 million in Series A funding from 8VC, a16z, Wing VC, Catalio, Alexandria Venture and others, with the purpose of advancing a pipeline of therapeutics designed to broaden the reach of next-generation cancer therapies, as well as conduct a breadth of discovery programs designed to identify novel, best-in-class target antigens across a range of cancer indications.
The company is led by young chief executive Kevin Parker (pictured above).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze